GLENZA 40 MG

Rather than viewing Enzalutamide only as a member of the androgen receptor signaling inhibitor class, its clinical role is better understood through the indications recorded here. Metastatic castration-resistant prostate cancer; non-metastatic castration-resistant prostate cancer; metastatic hormone-sensitive prostate cancer is the principal oncology use described in the database. Its entry covers several prostate-cancer states, including metastatic and non-metastatic castration-resistant disease and metastatic hormone-sensitive disease, rather than a single stage of illness. Inhibits androgen receptor signaling by blocking androgen binding, nuclear translocation and transcriptional activity. Hormone-pathway suppression is the central therapeutic principle, with treatment selection shaped by the prostate cancer disease state or other hormone-sensitive context described in the indication. The treatment is classified as Hormonal / Endocrine Therapy; Androgen Receptor Inhibitor and is associated with Prostate Cancer. Regimens listed include Enzalutamide + ADT; enzalutamide monotherapy where labeled. These examples show where the medicine is incorporated into treatment pathways and, where relevant, which agents accompany it. The database places it within endocrine management, where the hormonal environment and disease state are important determinants of clinical use. The pharmacologic mechanism provides context but does not by itself establish eligibility. This database entry is intended for clinical reference and not for individualized prescribing, dose selection, or treatment planning. Current product labeling and relevant guideline versions should be used to verify contemporary practice.